We found that knockdown of MeCP2 increased mRNA expression levels of epithelial markers E-Cadherin, and decreased mesenchymal markers, ZEB1, ZEB2, and TWIST1 in LN18 and U251 glioma cells (Fig. 3a-b). This evidence concerns the gene MECP2 and central nervous system cancer.